Anna H. Messner, MD

Professor of Otolaryngology-Head and Neck Surgery (Pediatrics) at the Stanford University Medical Center and the Lucile Salter Packard Children's Hospital, Emerita

Academic Appointments

Emeritus Faculty - University Medical Line, Otolaryngology (Head and Neck Surgery)

Administrative Appointments

Chief of Pediatric Otolaryngology/Head & Neck Surgery, Lucile Packard Children's Hospital at Stanford (2013 - Present)
Vice Chair, Department of Otolaryngology/Head & Neck Surgery (2004 - Present)
Otolaryngology residency program director, Dept of Otolaryngology/Head & Neck Surgery (2002 - Present)
Pediatric Otolaryngology Fellowship Director, Department of Otolaryngology/Head & Neck Surgery (2010 - Present)

Honors & Awards

AOA, Alpha Omega Alpha (1988)
Stanford Otolaryngology Resident Teacher of the Year Award, Stanford Dept of Otolaryngology (1997, 1998, 1999, 2000, 2008)
Otolaryngology Resident Advocate Award, Stanford Dept of Otolaryngology (2004, 2006)
Honor Award, American Academy of Otolaryngology/Head & Neck Surgery (2007)
American Academy of Otolaryngology/Head & Neck Surgery Distinguished Award for Humanitarian Efforts, American Academy of Otolaryngology/Head & Neck Surgery (2011)
2013 Kaiser Award for outstanding and innovative contributions to medical education, Stanford University (2013)

Boards, Advisory Committees, Professional Organizations

Member, American Society of Pediatric Otolaryngology (1999 - Present)
member, The Triological Society (2008 - Present)
member, American Academy of Otolaryngology-Head & Neck Surgery (1995 - Present)
member, Society for Ear, Nose & Throat Advances in Children (1996 - Present)
Member, American College of surgeons (2011 - Present)
Member, American Academy of Pediatrics (2005 - Present)
Member, Society of University Otolaryngologists (2004 - Present)
member, Otolaryngology Program Directors Organization (2009 - Present)

Professional Education

A.B., Duke University, Economics (1982)
M.D., Wake Forest University SOM, Medicine (1989)

Current Research and Scholarly Interests

Dr. Anna Messner's academic focus is on the care of children with common pediatric disorders who are undergoing surgery. Specifically she has research projects in the area of post-tonsillectomy care, obstructive sleep apnea and ankyloglossia. Dr. Messner is also pursing projects in the area of education of medical professionals at all levels.

Clinical Trials

Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Use in Pediatric Procedures Not Recruiting
More
THRIVE (Transnasal Humidified Rapid-Insufflation Ventilatory Exchange) refers to the use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia. The use of high-flow nasal cannula oxygen supplementation during anesthesia for surgical procedures has been a recent development in the adult population, with limited data analyzing the pediatric population. This study will determine whether high flow nasal cannula oxygen supplementation during surgical or endoscopic procedures can safely prevent desaturation events in children under anesthesia.

Stanford is currently not accepting patients for this trial. For more information, please contact Thomas J Caruso, M.D., M.Ed., 650-723-5728.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details
In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms? Not Recruiting
More
All neonates, ages 0 to 4 months, presenting to LPCH pediatric ENT clinic for airway difficulties or stridor will be screened for inclusion. As is consistent with an acceptable standard of medical care, these children will undergo a flexible nasal endoscopic exam to make the diagnosis of laryngomalacia, as well as be weighed and a breastfeeding history taken. If laryngomalacia is present, the study staff with then administer the Infant Gastroesophageal Reflux Questionnaire (IGERQ) and an airway symptoms questionnaire (ASQ). Those babies with an IGERQ score of less than sixteen (no more than mild reflux) and an ASQ score greater than six will be eligible for randomization. The patient will then be randomly placed in the control group (placebo) or the intervention group (ranitidine 2mg/kg every 12 hours or famotidine 0.5 mg/kg daily). Patients will stay on medication for a minimum of 6 months, or until symptoms resolve. Patients will be seen in follow up at 1, 2, 3, 4, 5, 6, 8 and 10 months. At which time I-GERQ, ASQ and weights will be taken. The primary outcome measure will be the time for the ASQ score to drop to normal on ranitidine or famotidine versus placebo. A secondary outcome will be weight gain in percentile. If the patient's I-GERQ score goes above 16 at any time in the study, the patient will be crossed over to the treatment arm and started on medical treatment.

Stanford is currently not accepting patients for this trial. For more information, please contact Lorene Nelson, PhD, 650-723-6854.

Lead Sponsor
- Stanford University
Stanford Investigators
View full details

2023-24 Courses

Independent Studies
- Directed Reading in Otolaryngology
  OTOHNS 299 (Win)
- Medical Scholars Research
  OTOHNS 370 (Aut, Win, Spr, Sum)

Find a doctor

Clinics & Services

Research Resources

Professional Training

Education Resources